With India’s population of about 1.45 billion, it may be fair to say that its healthcare realm may be imperfect, though there may be advancements to augment it. But, what are the creases that need to be ironed to make healthcare more accessible and affordable for India’s citizens, while also being viable to its pharma companies? Can both objectives be met in one go? How has regulation made pharmaceuticals more conducive to India’s diverse landscape?
In the latest episode of CAM Radio – Clear Cut, our Partner (Head – Pharma & Healthcare) Ashwin Sapra in conversation with Shrija Agrawal of Rizing explores the ramifications of the prices of essential life-saving drugs and medical devices coming down, how the DPCO (Drug Price Control Order) aims to impose a pricing mechanism on pharma companies, why pharma MSMEs may have trouble maintaining high-quality standards, whether the pharmaceutical space in India is a winner-take-all market, whether the UCPMP (Uniform Code of Pharmaceuticals Marketing Practices) has made pharma companies rethink promotional activities, to what extent pharma companies are responsible for the rising cost of healthcare, whether India would ever tangibly have universal healthcare and more.
